-
Product Insights
NewElectrophysiology Ablation Catheters Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Electrophysiology Ablation Catheters Pipeline Market Report Overview Electrophysiology ablation is applicable for a wide variety of arrhythmias and has an extremely high success rate with low rates of complication and recurrence. The electrophysiology ablation catheters pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and...
-
Innovation Ranking
NewInnovation Ranking – Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc (Fulcrum Therapeutics) is a drug development company. The company is involved in the discovery and development of small molecule therapies to unlock gene regulation in diseases. Its pipeline products include losmapimod for treating facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058 for treating sickle cell disease and β Thalassemia. The company also owns a proprietary product engine FulcrumSeek, which detects drug targets that can control gene expression and treat the root cause of gene misexpression. The company’s key therapeutic...
-
Product Insights
Myotonic Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Myotonic Dystrophy - Drugs In Development, 2023’, provides an overview of the Myotonic Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myotonic Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Friedreich Ataxia – Drugs In Development, 2023
Global Markets Direct’s, ‘Friedreich Ataxia - Drugs In Development, 2023’, provides an overview of the Friedreich Ataxia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Friedreich Ataxia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Recessive X Chromosome Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Recessive X Chromosome Disorders - Drugs In Development, 2023’, provides an overview of the Recessive X Chromosome Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recessive X Chromosome Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Duchenne Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Duchenne Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Duchenne Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Sickle Cell Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Sickle Cell Disease - Drugs In Development, 2023’, provides an overview of the Sickle Cell Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sickle Cell Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Facioscapulohumeral Muscular Dystrophy (FSHD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Facioscapulohumeral Muscular Dystrophy (FSHD) - Drugs In Development, 2023’, provides an overview of the Facioscapulohumeral Muscular Dystrophy (FSHD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Facioscapulohumeral Muscular Dystrophy (FSHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GFH-009 in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GFH-009 in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) Drug Details: GFH-009...